Treace Medical Concepts, Inc.
TMCI- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001630627
In the last 90 days, Treace Medical Concepts, Inc. insiders filed 1 open-market purchase and 0 sales; 116 institutions reported holding it in 13F filings for Q2 2026, worth $126.8M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $246.7K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 116
- 13F valueReported value at the end of Q2 2026
- $126.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TMCI, Q2 2026
No superinvestor reported holding TMCI at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Treace Medical Concepts, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 24, 2026 (view filing)5:00 PM ET | Aug 20-24 | 4 days | Treace John T.Chief Executive Officer | PPurchase | +55.9K | $4.41 | +$246.7K | +0.8%7.40M after | 3 lots |
| Jun 12, 2026 (view filing) | Jun 10-11 | 2 days | Treace John T.Chief Executive Officer | PPurchase | +24.6K | $4.03 | +$99.1K | +0.3%7.35M after | Amended2 lots |
| Jun 1, 2026 (view filing) | Jun 1 | Same day | Treace John T.Chief Executive Officer | PPurchase | +50.0K | $3.56 | +$178.0K | +0.7%7.32M after | |
| May 28, 2026 (view filing) | May 26-28 | 2 days | Treace John T.Chief Executive Officer | PPurchase | +115.5K | $2.95 | +$340.4K | +1.6%7.27M after | 3 lots |
| May 14, 2026 (view filing) | May 12-14 | 2 days | Treace John T.Chief Executive Officer | PPurchase | +153.8K | $2.44 | +$375.7K | +2.2%7.16M after | 3 lots |
| Mar 19, 2025 (view filing) | Mar 17 | 2 days | Scanlan Sean F.Chief Innovation Officer | SSale | −50.0K | $7.97 | −$398.5K | −12.1%364.1K after | 10b5-1 |
| Mar 4, 2025 (view filing) | Mar 4 | Same day | Treace John T.Chief Executive Officer | PPurchase | +60.0K | $8.73 | +$523.8K | +0.9%6.80M after | |
| Sep 17, 2024 (view filing) | Sep 16 | 1 day | Treace John T.Chief Executive Officer | PPurchase | +50.0K | $5.31 | +$265.5K | +0.8%6.52M after | |
| Aug 19, 2024 (view filing) | Aug 15 | 4 days | Treace James TDirector | PPurchase | +84.0K | $5.96 | +$500.6K | +7.4%1.22M after | |
| Aug 15, 2024 (view filing) | Aug 14 | 1 day | Treace John T.Chief Executive Officer | PPurchase | +85.0K | $6.00 | +$510.0K | +1.3%6.47M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Treace Medical Concepts, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 6,364,000 | $25.3M | 0.70% | 00.0% | Unchanged |
| Bank of America Corp | 3,305,100 | $13.2M | 0.00% | +90,807+2.8% | Added |
| Gagnon Securities LLC | 3,029,543 | $12.1M | 2.32% | −2,172,343−41.8% | Reduced |
| Vanguard Capital Management LLC | 2,028,479 | $8.07M | 0.00% | +566,972+38.8% | Added |
| Gagnon Advisors, LLC | 1,534,034 | $6.11M | 3.88% | +1,534,034 | New |
| AQR Capital Management LLC | 1,497,673 | $5.96M | 0.00% | +435,833+41.0% | Added |
| BlackRock, Inc. | 1,380,021 | $5.49M | 0.00% | −1,960,002−58.7% | Reduced |
| Marshall Wace, LLP | 1,328,592 | $5.29M | 0.00% | +1,063,659+401.5% | Added |
| CIBC Bancorp USA Inc. | 1,216,044 | $4.84M | 0.01% | −2,309−0.2% | Reduced |
| Acadian Asset Management LLC | 928,177 | $3.69M | 0.00% | −13,116−1.4% | Reduced |